Catalyst Wire Dossier Catalyst Wire Dossier

KH658 gene therapy

· Chengdu Origen Biotechnology Co., Ltd.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for KH658 gene therapy, covering 2024-11-29 to 2026-01-08. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration [Phase 1]

See pricing